DE4207704A1 - Use of aq. emulsion of dimeticon as mouth rinse against plaque - reducing bacterial growth and adhesion of bacteria in mouth - Google Patents

Use of aq. emulsion of dimeticon as mouth rinse against plaque - reducing bacterial growth and adhesion of bacteria in mouth

Info

Publication number
DE4207704A1
DE4207704A1 DE19924207704 DE4207704A DE4207704A1 DE 4207704 A1 DE4207704 A1 DE 4207704A1 DE 19924207704 DE19924207704 DE 19924207704 DE 4207704 A DE4207704 A DE 4207704A DE 4207704 A1 DE4207704 A1 DE 4207704A1
Authority
DE
Germany
Prior art keywords
dimeticon
mouth
plaque
emulsion
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19924207704
Other languages
German (de)
Inventor
Knut Dr Fischer
Knut Prof Dr Merte
Goetz Dr Nowak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19924207704 priority Critical patent/DE4207704A1/en
Publication of DE4207704A1 publication Critical patent/DE4207704A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/89—Polysiloxanes
    • A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A61K8/585—Organosilicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cosmetics (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)

Abstract

Dimeticon is used, in the form of an aq. emulsion, as a mouth rinse against plaque. The emulsion contains 0.1-5 vols.% of dimeticon. ADVANTAGE - The rinse is simple to use, physiologically acceptable and efficient in combatting plaque. It limits bacterial growth, kills microbes, and reduces the adhesion of bacteria in the mouth. It has no side effect

Description

Die Erfindung betrifft die Verwendung von Dimeticon in der Zahnheil­ kunde.The invention relates to the use of Dimeticon in dentistry customer.

Dimeticon ist der WHO-Name für Methylsilikonöl, das aus Polydimethyl­ siloxanen verschiedener Kettenlängen besteht:Dimeticon is the WHO name for methyl silicone oil, which is made from polydimethyl There are siloxanes of different chain lengths:

Dimeticon ist chemisch inert, unterliegt keiner Verderbnis (sog. Ranzigwerden) und zeichnet sich durch ein exzellentes Wasserabweisungsver­ mögen aus.Dimeticon is chemically inert and is not subject to corruption (so-called Rancid) and is characterized by an excellent water repellency like out.

Desweiteren ist Dimeticon farblos, geruchlos, geschmacklos und tempe­ raturstabil. Im Magen-Darm-Bereich erfolgt keine Resorption, die Substanz ist völlig atoxisch und wird unverändert wieder ausgeschieden.Furthermore, Dimeticon is colorless, odorless, tasteless and temp stable against raturation. There is no absorption in the gastrointestinal area, the substance is completely non-toxic and is excreted unchanged.

Nach epidemilogischen Erhebungen leiden sehr viele Menschen an einer Entzündung des Zahnfleisches (Gingivitis). Wird diese Gingivitis chronisch, kommt es in der Folge zu einer krankhaften und irreversiblen Veränderung des Zahnhalteapparates, zur Periodontitis, mit dem drohenden Verlust von Zähnen durch deren Lockerung im Knochen.According to epidemological surveys, many people suffer from one Inflammation of the gums (gingivitis). If this gingivitis becomes chronic, this leads to a pathological and irreversible change the periodontitis, with the impending loss of Teeth by loosening them in the bone.

Verantwortlich für die Ausbildung der Gingivitis bzw. Periodontitis ist der sich auf den Zähnen bildende Zahnbelag (miokrobielle Plaque). Daher wird die Entfernung bzw. Reduzierung der mikrobiellen Plaque und ihrer kristallinen Sekundär-Verfestigungen (Zahnstein) als wichtigste Maßnahme gegen Gingivitis und Periodontitis angesehen.Responsible for the development of gingivitis or periodontitis  is the plaque that forms on the teeth (miocrobial plaque). Therefore is the removal or reduction of the microbial plaque and its crystalline secondary consolidation (tartar) as the most important measure against gingivitis and periodontitis.

Am wirksamsten ist der Plaquebildung durch eine regelmäßige häusliche Zahnpflege sowie eine in zeitlichen Abständen von einem Zahnarzt durchge­ führte Zahnsteinentfernung zu begegnen.The most effective is the formation of plaque through a regular home Dental care as well as a periodic check by a dentist led to counter tartar removal.

Darüber hinaus sind aber auch schon verschiedene Präparate und chemi­ sche Verbindungen zur medikamentellen Beeinflussung der Plaque (Reduzierung durch Mundspülung) geprüft worden, bzw. im Einsatz, wobei aber in allen Fällen Nebenwirkungen zu verzeichnen sind, die eine stark eingeschränkte Verwendbarkeit dieser Mittel bedingen. So besteht bei Verwendung von Anti­ biotika die Gefahr der Sensibilisierung und Resistenzbildung, und bei Ver­ wendung von Wasserstoffperoxid die Gefahr von Gasembolien periodentaler Gefäße. Desweiteren haben einige medizinische Zahnspülungen aufgrund darin enthaltener Substanzen (Hydroxichinolinsulfat, Phenolderivate, Guanidine, Zinnchlorid, Chlorhexidin) Geschmacksirritationen, eine Braunfärbung von Zähnen und Zunge sowie noch nicht verifizierte Auswirkungen auf die Mund­ flora und andere nicht abschätzbare Risiken zur Folge. Beim Einsatz enzyma­ tischer Mittel ist eine nicht realisierbare Verweildauer im Mundraum erfor­ derlich, um eine Wirkung zu erzielen.In addition, there are also various preparations and chemi connections to medicinally influencing plaque (reduction by mouthwash), or in use, but in all Cases of side effects have been reported that are severely limited Condition availability of these funds. So there is when using anti biotics the risk of sensitization and resistance formation, and in ver use of hydrogen peroxide increases the risk of gas embolism more periodically Vessels. Furthermore, some have medical rinses due to it contained substances (hydroxyquinoline sulfate, phenol derivatives, guanidines, Tin chloride, chlorhexidine) taste irritation, a brown color of Teeth and tongue and effects on the mouth that have not yet been verified flora and other unpredictable risks. When using enzyma tical means, an unrealizable length of stay in the oral cavity is required necessary to have an effect.

Aufgabe der Erfindung ist es daher, ein Mundspülmittel zur Verfügung zu stellen, das problemlos und einfach angewendet werden kann, physiolo­ gisch unbedenklich ist sowie eine erfolgreiche Plaquebekämpfung ermöglicht.The object of the invention is therefore to provide a mouthwash that can be used easily and easily, physiolo is harmless and enables successful plaque control.

Überraschenderweise wurde gefunden, daß Dimeticon ausgezeichnet als Mundspülmittel gegen Plaque geeignet ist. Dimeticon wird dabei in in Form einer wäßrigen Emulsion eingesetzt, in der sein Volumenanteil vorzugsweise 0,1-5% beträgt. Um den Geschmack des Spülmittels zu verbessern, können entsprechende Zusatzstoffe enthalten sein.Surprisingly, Dimeticon was found to be excellent as Mouthwash is suitable for plaque. Dimeticon gets in shape an aqueous emulsion, in which its volume fraction is preferred Is 0.1-5%. To improve the taste of the detergent, you can appropriate additives may be included.

Dimeticon-Spülflüssigkeit zeigt eine hervorragende plaquereduzierende Wirkung durch Einschränkung des bakteriellen Wachstums (bakteriologischer Effekt), direkte Abtötung von Mikroben (bakteriozider Effekt) und Verminde­ rung der Haftung von Bakterien im Mundbereich.Dimeticon rinsing liquid shows an excellent plaque-reducing Effect by restricting bacterial growth (bacteriological Effect), direct killing of microbes (bacteriocidal effect) and people  the adhesion of bacteria in the mouth area.

Aufgrund der völligen Freiheit von Nebenwirkungen kann Dimeticon aus zahnmedizinischer Sicht ohne Einschränkungen angewendet werden. Damit steht neben den bisher bekannten Substanzen zur Hemmung bzw. Reduzierung der Plaque-Bildung ein Vertreter einer neuen Medikamenten-Generation zur Ver­ fügung.Because of the complete freedom from side effects, Dimeticon can be made dental perspective can be applied without restrictions. With that stands in addition to the previously known substances for inhibiting or reducing the Plaque formation is a representative of a new drug generation for ver addition.

Die Erfindung wird nachstehend anhand einer durchgeführten klinischen Untersuchung näher erläutert:The invention is carried out on the basis of a clinical Investigation explained:

Untersucht wurde eine Gruppe aus sieben Probanden beiderlei Ge­ schlechts im Alter zwischen 24 und 47 Jahren (Mittelwert 38 Jahre). Die Dauer der Untersuchung betrug insgesamt sechs Monate. Dieser Zeitraum un­ tergliederte sich in einen dreimonatigen Vergleichszeitraum und einen drei­ monatigen Spülzeitraum. Im Vergleichszeitraum betrieben die Probanden eine normale häusliche Zahnpflege, während im Spülzeitraum zusätzlich einmal am Tag mit Dimeticon gespült wurde. Dabei kam Dimeticon in Form einer wäßrigen Emulsion mit einem Volumenanteil von 1-2% zum Einsatz.A group of seven subjects of both types was examined poor between the ages of 24 and 47 (mean 38 years). The The total duration of the investigation was six months. This period un divided into a three-month comparison period and a three monthly flushing period. In the comparison period, the subjects operated one normal home dental care, while once in the rinsing period Day with Dimeticon. Dimeticon came in the form of an aqueous one Emulsion with a volume share of 1-2% is used.

Die Untersuchung fand an insgesamt neun Tagen statt, die sich in eine Basisuntersuchung am Beginn des Untersuchungszeitraumes, eine Startunter­ suchung zu Beginn des Vergleichszeitraumes, drei Kontrolluntersuchungen innerhalb dieses Zeitraumes, einer Startuntersuchung zu Beginn des Spül­ zeitraumes, sowie drei weitere Kontrolluntersuchungen innerhalb dieses Zeitraumes untergliederte.The investigation took place over a total of nine days Basic examination at the beginning of the examination period, a start sub Search at the beginning of the comparison period, three check-ups within this period, a start examination at the beginning of the rinse period, as well as three further check-ups within this Period.

Die Einzelbefunde zu den verschiedenen untersuchten klinischen Para­ metern wurden durch Mittelwertbildung verdichtet. Im einzelnen konnten folgende Ergebnisse erzielt werden:The individual findings on the various clinical para examined meters were compressed by averaging. In detail could the following results can be achieved:

  • - Mikrobielle Plaque-Masse (Plaqueindex nach SILNESS un. LÖE)
    Die relative Reduktion der Plaque beträgt nach Dimeticon-Anwendung 46,0%.     - Microbial plaque mass (plaque index according to SILNESS and LÖE)
    The relative reduction in plaque after Dimeticon application is 46.0%.
  • - Gingivitis (Gingivaindex Nach LÖE u. SILNESS)
    Diese krankhaften Veränderungen konnten durch Dimeticon um 24,1 % ver­ mindert werden.    - Gingivitis (Gingiva index according to LÖE and SILNESS)
    Dimeticon reduced these pathological changes by 24.1%.
  • - Attachmentniveau (Bewertungsmaß der Zahnbefestigung)
    Eine klinisch erfaßbare Zunahme der Zahnbefestigung im Ergebnis der Be­ handlung war objektiv festzustellen.    - Attachment level (assessment of the tooth attachment)
    A clinically detectable increase in tooth fixation as a result of the treatment was objective.
  • - Zahnsteinneubildung
    Bei Dimeticon-Anwendung konnte eine verminderte Zahnsteinneubildung von 8,3% gegenüber der Vergleichsphase als Ausdruck und Folge der reduzier­ ten Plaque-Masse gefunden werden.    - Tartar formation
    When using Dimeticon, a reduced formation of new tartar of 8.3% compared to the comparison phase could be found as an expression and result of the reduced plaque mass.

Claims (2)

1. Verwendung von Dimeticon, dadurch gekennzeichnet, daß es in Form einer wäßrigen Emulsion als Mundspülmittel gegen Plaque einge­ setzt wird.1. Use of Dimeticon, characterized in that it is used in the form of an aqueous emulsion as a mouthwash against plaque. 2. Verwendung von Dimeticon nach Anspruch 1, dadurch gekennzeich­ net, daß sein Volumenanteil in der wäßrigen Emulsion 0,1-5% be­ trägt.2. Use of Dimeticon according to claim 1, characterized net that its volume fraction in the aqueous emulsion be 0.1-5% wearing.
DE19924207704 1992-03-11 1992-03-11 Use of aq. emulsion of dimeticon as mouth rinse against plaque - reducing bacterial growth and adhesion of bacteria in mouth Withdrawn DE4207704A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19924207704 DE4207704A1 (en) 1992-03-11 1992-03-11 Use of aq. emulsion of dimeticon as mouth rinse against plaque - reducing bacterial growth and adhesion of bacteria in mouth

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19924207704 DE4207704A1 (en) 1992-03-11 1992-03-11 Use of aq. emulsion of dimeticon as mouth rinse against plaque - reducing bacterial growth and adhesion of bacteria in mouth

Publications (1)

Publication Number Publication Date
DE4207704A1 true DE4207704A1 (en) 1993-09-16

Family

ID=6453772

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19924207704 Withdrawn DE4207704A1 (en) 1992-03-11 1992-03-11 Use of aq. emulsion of dimeticon as mouth rinse against plaque - reducing bacterial growth and adhesion of bacteria in mouth

Country Status (1)

Country Link
DE (1) DE4207704A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5393745A (en) * 1993-12-02 1995-02-28 Schmidt; Alfred Method for treating aphthae using dimethylpolysiloxane
WO2005002535A1 (en) * 2003-07-03 2005-01-13 Betafarma S.P.A. Antibacterial mouthwash
WO2012057895A2 (en) 2010-10-26 2012-05-03 Quinnova Pharmaceuticals, Inc. Composition and method for treating wounds

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5393745A (en) * 1993-12-02 1995-02-28 Schmidt; Alfred Method for treating aphthae using dimethylpolysiloxane
WO2005002535A1 (en) * 2003-07-03 2005-01-13 Betafarma S.P.A. Antibacterial mouthwash
WO2012057895A2 (en) 2010-10-26 2012-05-03 Quinnova Pharmaceuticals, Inc. Composition and method for treating wounds
EP2632432A2 (en) * 2010-10-26 2013-09-04 Quinnova Pharmaceuticals, Inc. Composition and method for treating wounds
EP2632432A4 (en) * 2010-10-26 2014-04-02 Quinnova Pharmaceuticals Inc Composition and method for treating wounds
US9345720B2 (en) 2010-10-26 2016-05-24 Exeltis Usa Dermatology, Inc. Composition and method for treating wounds

Similar Documents

Publication Publication Date Title
Brecx et al. Efficacy of Listerine®, Meridol® and chlorhexidine mouthrinses on plaque, gingivitis and plaque bacteria vitality
DE69211682T2 (en) AGENT AGAINST DENTAL COATING COMPOSED OF NON-ANTIBACTERIAL TETRACYCLINE
Lang et al. Optimal dosage of chlorhexidine digluconate in chemical plaque control when applied by the oral irrigator
Quirynen et al. The efficacy of amine fluoride/stannous fluoride in the suppression of morning breath odour
Tinanoff et al. Effect of stannous fluoride mouthrinse on dental plaque formation
DD202245A5 (en) PROCESS FOR PRODUCING ORAL COMPOSITIONS
DE3882775T2 (en) Composition for the treatment of periodontal disease.
Zimmermann et al. Gingivitis, plaque accumulation and plaque composition under long‐term use of Meridol®
DE2510412A1 (en) GINGIVITIS MEDICINAL PRODUCTS
DE69110125T2 (en) TOOTHPASTE AGAINST DENTAL COATING.
Eaton et al. The effects of a 0.12% chlorhexidine‐digluconate‐containing mouthrinse versus a placebo on plaque and gingival inflammation over a 3‐month period
EP0966256B1 (en) Agents for promoting oral hygiene and oral health
Overholser Jr Longitudinal clinical studies with antimicrobial mouthrinses
DE102017005168A1 (en) Preparation for use in the oral cavity
Gillam et al. Clinical efficacy of a low abrasive dentifrice for the relief of cervical dentinal hypersensitivity
DE3011437A1 (en) PHARMACEUTICAL AGENT FOR HEALING INFLAMMABLE AND / OR DEGENERATIVE AND / OR ATROPHIC MUSCULAR DISEASES
EP0480172B1 (en) Preparation for the care of the teeth
DE68909604T2 (en) ANTIMICROBIAL COMPOSITION WITH LONGER EFFECT.
Lang et al. Effect of chlorhexidine (0.12%) rinses on periodontal tissue healing after tooth extraction: (I). Clinical parameters
DE4207704A1 (en) Use of aq. emulsion of dimeticon as mouth rinse against plaque - reducing bacterial growth and adhesion of bacteria in mouth
EP2192891B1 (en) Material composition for oral hygiene product
Quirynen et al. Comparative antiplaque activity of sanguinarine and chlorhexidine in man
Etemadzadeh et al. Lacking anti‐plaque efficacy of 2 sanguinarine mouth rinses
Linčir et al. Caries-preventive effect of two different topical fluoride concentrations with two different frequencies of application in preschool children
Tilliss et al. Use of toothpicks for chlorhexidine S‐M staining

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8130 Withdrawal